Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc – Xenetic to receive one-time payment of $7.5M and single digit royalty payments based upon net sales –Sublicense Agreement • November 2nd, 2017 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This press release is not intended to describe this transaction in its entirety and readers are encouraged to review the Form 8-K the Company filed with the Securities and Exchange Commission today.
